aTyr Pharma to Participate in September Investor Conferences
Details of the conferences appear below:
Conference:
Date:
Location:
Format: 1x1 Investor Meetings
Conference:
Date:
Time:
Location:
Format: Corporate Presentation
Conference:
Date:
Time:
Location:
Format: Corporate Presentation
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of the H.C. Wainwright and
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
Source: aTyr Pharma, Inc.